HK Stock MarketDetailed Quotes

06185 CANSINOBIO

Watchlist
  • 34.100
  • -0.200-0.58%
Market Closed Mar 28 16:08 CST
8.44BMarket Cap-20.63P/E (TTM)

About CANSINOBIO Company

The company was founded in 2009 in China with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines, and is an industry-leading high-tech biological products enterprise. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is currently mainly engaged in vaccine research, development, production and commercialization. The main commercialized and ongoing products are meningococcal conjugate vaccine, pneumococcal conjugate vaccine, component 100 DPT vaccine, recombinant polio vaccine, etc. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Collective, and the company has won various honors such as Tianjin Manufacturing Individual Champion Enterprise, Tianjin Specialized and New Small and Medium Enterprises, and Tianjin Advanced Smart Factory.

Company Profile

Symbol06185
Company NameCANSINOBIO
ISINCNE100003F01
Listing DateMar 28, 2019
Issue Price22.00
Shares Offered57.25M share(s)
FoundedJan 13, 2009
Registered AddressChina
ChairmanXuefeng YU
Secretaryjinzhaomingjing cui
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants, Deloitte Huayong Certified Public Accountants (Special General Partnership)
Company CategoryOther
Registered Office401-420, 4th Floor, West District Biomedical Park, No. 185 South Street, West District, Tianjin Economic and Technological Development Zone
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees1494
MarketHong Kong motherboard
Phone022-58213766
Fax022-58213626
Emailir@cansinotech.com
BusinessLicense items: Class III medical device business; pharmaceutical production; pharmaceutical import and export; drug retail; pharmaceutical wholesale; import and export of goods; technology import and export. (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments. Specific business projects are subject to documents or licenses approved by relevant departments) General projects: Class I medical device sales; Class II medical device sales; medical research and experimental development; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion. (With the exception of projects subject to approval according to law, independently carry out business activities based on a business license in accordance with the law)

Company Executives

  • Name
  • Position
  • Salary
  • Xuefeng YU
  • Chairman of the Board, CEOs, Executive Director, General Manager, Member of the Remuneration and Assessment Committee, Nomination Committee Members, Authorized Representative
  • --
  • Shou Bai CHAO
  • Executive Director, Deputy General Manager, Chief Operating Officer
  • --
  • jing wang
  • Executive Director, Deputy General Manager, Chief Commercial Officer
  • --
  • shuifa gui
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • --
  • jianzhong liu
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
  • --
  • yaoliang zhang
  • Independent Non-Executive Director, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee, Nomination Committee Members
  • --
  • zhongqi shao
  • Non-employee Representative Supervisor
  • --
  • zhi xiao
  • Chairman of the Supervisory Board, Non-employee Representative Supervisor
  • --
  • chang sun
  • Employee Representative Supervisor
  • --
  • jin cui
  • Joint Company Secretary, Board Secretary
  • --
  • mingjing zhao
  • Joint Company Secretary, Authorized Representative
  • --
  • tao zhu
  • Chief Scientific Officer
  • --
  • Dongxu QIU
  • Deputy General Manager, Senior Vice President
  • --
  • zhicheng li
  • Non-executive Directors, Nomination Committee Members
  • --

Market Insights

Robotics Investment Opportunities Robotics Investment Opportunities

Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors. Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors.

Unlock Now
Discussing
北水爆買!中國資產能否延續漲勢?
3月17日早盤,地產代理、物業服務及管理等板塊漲幅明顯,貝殼-W早盤漲逾4%,碧桂園服務漲逾9%。政策消息面上,兩部門發文落實專項債支持收地,中房協組織民營房企座談會。中國資產本輪火爆行情還能持續多久?你會如何投資? Show More
Positive signs keep on coming! China's assets explode across the board
Following the announcement of a series of previous stimulus policies, and DeepSeek's popularity with its low cost and high performance advantages, China Securities sounded the horn of counterattack this year.